Abstract
Introduction

Gastrointestinal stromal tumour (GIST) is the most common mesenchymal neoplasm of the gastrointestinal tract, comprising the majority of tumours previously diagnosed as leiomyomas, leiomyoblastomas, leiomyosarcomas, neurofibromas and schwannomas. GISTs are believed to originate from intersticial cells of Cajal (the pacemaker cells of the gastrointestinal tract) or related stem cells, and are characterized by KIT or platelet-derived growth factor receptor alpha (PDGFRA) activating mutations
.
Recent population-based studies in Europe revealed annual incidences of 10-20 per million, and the prevalence was estimated at 129 per million [7] [8] [9] . About 4500-6000 new cases of GIST are diagnosed each year in the USA [10] .
GISTs have an equal sex predilection, and most tumours occur in individuals over the age of 50. GISTs are very rare in children (Ͻ1%) [1, 2, 11, 12] . [1, 2, [13] [14] [15] [16] [17] [18] [19] [20] .
GIST occurs throughout the gastrointestinal tract. The most common sites are the stomach (50%) and small bowel (25%). Approximately 10% of GISTs arise in the colon and rectum and 5% within the oesophagus. About 10% of the cases occur outside of the gastrointestinal tract (extra-gastrointestinal GISTs), mainly in the mesentery, omentum, retroperitoneum and pelvis
The most common clinical presentation of GIST is gastrointestinal bleeding. Acute Table 2 ) [4, 40, 41] . KIT [1, 56, 57] . [58, 59] . (Fig. 2) [59, 64] . The standard starting dose of imatinib is 400-600 mg daily, even though 600 mg proved not to be superior to 400 mg [59] , and continuous administration of imatinib is recommended in the treatment of advanced disease with no upper limit for treatment duration as discontinuation of treatment was associated with disease progression. Only tumour progression, intolerance or patient refusal should encourage interruption of treatment [65] . [66] . [58, [67] [68] [69] [70] [71] [72] [73] [58, [73] [74] [75] .
Imatinib and implications of mutation status for the treatment of GIST
The use of imatinib has revolutionized the management of unresectable and metastatic GISTs and altered its natural history, substantially improving survival time and delaying disease progression in many patients
Imatinib (STI571) was the first targeted therapy approved for the treatment of GIST, and it has become the treatment of choice for advanced GIST. Imatinib is an orally available tyrosine kinase inhibitor of KIT and PDGFRA receptors first developed as a treatment for chronic myeloid leukemia by inhibiting the intracellular kinases ABL and BCR-ABL fusion protein [60-63]. Imatinib blocks the transfer of phosphate groups from adenosine triphosphate to tyrosine residues of the substrates. This results in interruption of the downstream signalling cascade that regulates cell proliferation
Response monitoring is carried out using computed tomography (CT), magnetic resonance imaging (MRI) and/or metabolic imaging with fluorodeoxyglucose-positron emission tomography (FDG-PET). GIST liver metastases generally turn into hypodense lesions with cystic degeneration on CT scans
Adverse effects of imatinib therapy are usually mild to moderate. The most common are oedema (particularly periorbital), muscle cramps in fingers and feet, diarrhoea, nausea and vomiting, fatigue and rash. Haematological disturbances may occur, including anaemia and neutropenia. Elevation in liver transaminase levels is also common [32]. The success of imatinib in controlling advanced GIST led to interest in the neoadjuvant and adjuvant use of the drug. The neoadjuvant (preoperative) use of imatinib is recommended to facilitate resection and avoid mutilating surgery by decreasing tumour size. The use of neoadjuvant imatinib therapy was considered safe with encouraging outcomes
. Adjuvant therapy is indicated for patients at high risk of recurrence. It was demonstrated that imatinib at 400 mg daily for 1 year following surgical resection prolongs recurrence-free survival and is associated with improved overall survival
Pathologists [48-50, 76, 77] .
In conclusion, routine tumour genotyping is recommended if tyrosine kinase inhibition therapy is considered for the treatment of GIST.
Imatinib resistance in GIST
A minority of patients (10-20%) experience tumour growth on imatinib within the first 6 months of treatment (primary resistance), and PDGFRA D842V and KIT exon 9 (under standard imatinib dose therapy) mutations as well as wild-type genotype may explain primary resistance. However, the causes for such resistance remain largely unknown [58] .
The vast majority of patients who responded to imatinib will develop tumour progression (secondary resistance). Secondary resistance (Fig. 3) [78] [79] [80] [81] [82] [83] [84] .
Another possible mechanism of imatinib resistance is KIT gene amplification [79] , and other oncogenes and tumour suppressor genes may also be responsible for sustaining the tumourigenic potential in imatinib-resistant GISTs. Moreover, the constitutive activation of downstream-signalling proteins (kinase pathways) represents a distinct molecular mechanism of imatinib resistance, and the PI3-kinase/AKT may play an important role as an alternate survival pathway [81, 85] .
Multi-targeted tyrosine kinase inhibitors for the treatment of GIST
Multiple novel tyrosine kinase inhibitors may be potentially useful for the treatment of imatinib-resistant GISTs as they interfere with KIT and PDGFRA receptors or with the downstream-signalling proteins [86] . 
Sunitinib (SU11248) was approved for the treatment of imatinib-resistant GIST or imatinib-intolerant patients. Sunitinib
Fig. 3 Histopathological demonstration of imatinib resistance (haematoxylin and eosin, 200ϫ). (A) Spindle cell GIST before imatinib treatment. (B) Extensive hyalinization indicative of response to imatinib treatment. (C) Tumour growth near area of hyalinization (upper left) under imatinib treatment (secondary resistance
